EyeGene Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 91


  • Stock Symbol
  • 185490

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.27
  • (As of Tuesday Closing)

EyeGene General Information


EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
Corporate Office
  • B-1211, 401 Yangcheon-ro
  • Gangseo-gu
  • Seoul, 07528
  • South Korea
+82 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeGene Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.27 $2.27 $2.14 - $3.82 $61.5M 27M 85.7K -$0.75

EyeGene Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 59,589 59,589 39,391 275,212
Revenue 2,390 2,390 4,097 2,831
EBITDA (16,614) (16,614) (21,322) (28,273)
Net Income (16,143) (16,143) (20,086) (30,180)
Total Assets 60,607 60,607 63,648 88,226
Total Debt 1,669 1,669 1,898 3,314
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EyeGene Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Executive Team (5)

Name Title Board Seat Contact Info
Choi Seuk-Keun Ph.D Chief Executive Officer
Myeong Rhee Chief Financial Officer & Managing Director
Yangje Cho Ph.D Chief Technology Officer & Director
Hyung Su Yun Managing Director & Head of Business Development
You’re viewing 4 of 5 executive team members. Get the full list »

EyeGene Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeGene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NexThera 26-Mar-2024 00000 0000 00.000 Biotechnology
Novelty Nobility 30-Jan-2020 Early Stage VC 00.000 Drug Discovery
To view EyeGene’s complete investments history, request access »

EyeGene ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies











To view EyeGene’s complete esg history, request access »

EyeGene FAQs

  • When was EyeGene founded?

    EyeGene was founded in 2000.

  • Who is the CEO of EyeGene?

    Choi Seuk-Keun Ph.D is the CEO of EyeGene.

  • Where is EyeGene headquartered?

    EyeGene is headquartered in Seoul, South Korea.

  • What is the size of EyeGene?

    EyeGene has 91 total employees.

  • What industry is EyeGene in?

    EyeGene’s primary industry is Other Healthcare Technology Systems.

  • Is EyeGene a private or public company?

    EyeGene is a Public company.

  • What is EyeGene’s stock symbol?

    The ticker symbol for EyeGene is 185490.

  • What is the current stock price of EyeGene?

    As of 16-Apr-2024 the stock price of EyeGene is $2.27.

  • What is the current market cap of EyeGene?

    The current market capitalization of EyeGene is $61.5M.

  • What is EyeGene’s current revenue?

    The trailing twelve month revenue for EyeGene is $2.39M.

  • What is EyeGene’s annual earnings per share (EPS)?

    EyeGene’s EPS for 12 months was -$0.75.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »